This trial is for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. It examines whether a medicine called BI 907828 can help when other treatments have been unsuccessful. Participants take the medicine regularly and are monitored for changes in their health.
- Lung Cancer
- Bladder Cancer
- Solid Tumors
- Biliary Tract Cancer
- Pancreatic Cancer
1 Primary · 10 Secondary · Reporting Duration: Up to 50 months
1 Treatment Group
BI 907828 treatment arm
1 of 1
130 Total Participants · 1 Treatment Group
Primary Treatment: BI 907828 treatment arm · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals are currently enrolled in this experiment?
"Affirmative. According to information provided on clinicaltrials.gov, the medical trial is actively seeking qualified candidates and was initially posted in late November 2022 before its most recent update occurring on March 6th 2023. 130 participants must be sourced from a total of 18 sites for this study." - Anonymous Online Contributor
Is this research endeavor available for enrollment currently?
"Clinicaltrials.gov reveals that this clinical trial is still recruiting participants; it was initially posted on November 25th 2022 and underwent its latest revision on March 6th 2023." - Anonymous Online Contributor
Has the BI 907828 treatment arm obtained clearance from the FDA?
"Due to the lack of efficacy data, BI 907828's safety is estimated at a rating of 2. Although it has been through Phase 2 trials and there are some results indicating its security." - Anonymous Online Contributor
How many venues are providing data for this research?
"Presently, this research is occurring in 18 centres situated across Washington, Hat Yai and Bangkok. It is prudent for potential participants to select the closest location possible so as to reduce their travel costs should they choose to enroll." - Anonymous Online Contributor